Docking of Repurposed JAK Inhibitors on JAK/STAT Pathway Proteins in Leukemia
Thu, 24 Apr
|On Going Study
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway plays a crucial role in hematopoiesis and immune function. Aberrant activation of this pathway is strongly associated with hematological malignancies like leukemia. This study explores the potential of repurposed JA
Time & Location
24 Apr 2025, 7:00 pm – 11:00 pm
On Going Study
About the event
🔍 Background:
The JAK/STAT pathway is a critical signal transduction mechanism activated by cytokines and growth factors, involving JAK family kinases (JAK1, JAK2, JAK3, TYK2) and STAT transcription factors (e.g., STAT3, STAT5). In leukemia, mutations or dysregulation in JAKs or upstream receptors lead to constitutive activation of this pathway, driving uncontrolled cell proliferation, survival, and resistance to apoptosis.
Current treatment options for leukemia can be expensive, toxic, and sometimes ineffective in resistant forms. Drug repurposing—finding new therapeutic uses for existing drugs—offers a cost-effective and faster alternative to drug development.
💊 Aim of the Study:
This research aims to investigate the interaction of already-approved JAK inhibitors (e.g., Ruxolitinib, Tofacitinib, Baricitinib) with target proteins of the JAK/STAT pathway using in silico molecular docking techniques. The focus is to:
Evaluate binding affinity,